Harvard Bioscience, Inc. (HBIO): Are Hedge Funds Right About This Stock?

Now that we’ve mentioned the most bullish investors, let’s also take a look at some funds that dropped their entire stakes in the stock during the third quarter. It’s worth mentioning that Benjamin A. Smith’s Laurion Capital Management dropped the biggest stake of all the investors monitored by Insider Monkey, totaling an estimated $0.3 million in stock. Ben Levine, Andrew Manuel and Stefan Renold’s fund, LMR Partners, also dropped its stock, about $0.1 million worth.

Let’s go over hedge fund activity in other stocks – not necessarily in the same industry as Harvard Bioscience, Inc. (NASDAQ:HBIO) but similarly valued. We will take a look at Xcel Brands Inc (NASDAQ:XELB), FBR & Co (NASDAQ:FBRC), Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), and Perion Network Ltd (NASDAQ:PERI). This group of stocks’ market values are similar to HBIO’s market value.

As you can see these stocks had an average of 4 hedge funds with bullish positions and the average amount invested in these stocks was $9 million. That figure was $6 million in HBIO’s case. FBR & Co (NASDAQ:FBRC) is the most popular stock in this table. On the other hand Xcel Brands Inc (NASDAQ:XELB) is the least popular one with only 3 bullish hedge fund positions. Harvard Bioscience, Inc. (NASDAQ:HBIO) is not the most popular stock in this group but hedge fund interest is still above average. This is a slightly positive signal but we’d rather spend our time researching stocks that hedge funds are piling on. In this regard FBRC might be a better candidate to consider taking a long position in.

Disclosure: none.